Aura Biosciences, Inc. · NASDAQ:AURA
Aura Biosciences — ISOO 2022
11 slides from Aura Biosciences's conference presentation, June 2022
Slide 1: A Phase 2 Trial of belzupacap sarotalocan (AU-011) via Suprachoroidal Administration
A Phase 2 Trial of belzupacap sarotalocan (AU-011), a First- in-class Targeted Therapy for Choroidal Melanoma via Suprachoroidal (SC) Administration Ivana Kim, MD, MBA On Behalf of the AU-011 Investigators Ocular Melanoma Center Retina Service Massachusetts Eye and Ear ISOO 2022 June 2022
Slide 2: Financial Disclosures
Financial Disclosures • Allergan (Research support) • Aura Biosciences (Investigator) • Biophytis (Consultant) • Kodiak Sciences (Consultant) • Novartis (Consultant) 2
Slide 3: Targeted Oncology Platform: Virus-Like Drug Conjugates (VDCs)
Targeted Oncology Platform: Virus-Like Drug Conjugates (VDCs) Virus-Like Particles Conjugated to a Cytotoxic VDCs can Recognize Tumor Associated Payload to form the VDC HSPGs* Cx Virus-Like Particle (VLP) Cytotoxic Drug Virus-Like Drug Conjugate (VDC) Technology Platform Designed to Target Broad Ran
Slide 4: Belzupacap sarotalocan (AU-011) Is an Investigational VDC with a Novel Dual Mechanism of Action
Belzupacap sarotalocan (AU-011) Is an Investigational VDC with a Novel Dual Mechanism of Action Light-activated drug belzupacap sarotalocan (AU-011) AU-011 is a novel VDC that consists of an HPV derived VLP conjugated to ~200 molecules of phthalocyanine dye Kines et al; Cancer Immunology Research, M
Slide 5: Summary of Phase 1b/2 Trial of AU-011 via Intravitreal Administration
Summary of Phase 1b/2 Trial of AU-011 via Intravitreal Administration AU-011 was well tolerated with the majority of AEs transient and Safety managed with the standard of care Visual acuity preservation rate of 71-86% at 12 months even in Visual Acuity subjects with tumors close to the fovea or opti
Slide 6: Slide 6
Slide 7: Suprachoroidal Administration Optimizes Delivery to the Posterior Segment
Suprachoroidal Administration Optimizes Delivery to the Posterior Segment OcularOcular Exposure After IVT or SC Injection1 Exposure After IVT or SC Injection 20000 IVT AU-011 Concentration (ng/mL) SC 15000 Intravitreal (IVT) injection Suprachoroidal (SC) injection 10000 Optimize therapeutic index
Slide 8: Evaluating Suprachoroidal Administration to Determine Optimal Administration Route for Pivotal Trial
Evaluating Suprachoroidal Administration to Determine Optimal Administration Route for Pivotal Trial Ph2 SC Trial Design: Dose Escalation Phase 18 subjects enrolled to date ▪ Cohort 6 currently enrolling Single Dose Cohorts – Completed 20 μg 40 μg 40 μg ▪ 80µg dose and 3 cycles of therapy x 1 Laser
Slide 9: Phase 2 SC – Demonstrated Favorable Safety Profile To Date
Phase 2 SC – Demonstrated Favorable Safety Profile To Date Preliminary results All Treated Subjects (n=18) Treatment Related Adverse Events Grade I Grade II Grade III Total ▪ Majority of AEs were transient and resolved without clinical sequelae Anterior chamber cell/ inflammation 22.2% 0 0 22.2% Con
Slide 10: Targeted Suprachoroidal Delivery May Lead to an Improved Risk:Benefit Profile Compared to IVT
Targeted Suprachoroidal Delivery May Lead to an Improved Risk:Benefit Profile Compared to IVT administration Mild to moderate AEs overall and no related SAEs/DLTs observed to Favorable Tolerability date Reduced Intraocular Minimal anterior uveitis and no vitiritis observed to date Inflammation No pi
Slide 11: Clinical Investigators & Participating Sites
Clinical Investigators & Participating Sites AU-011 Ocular Oncology Investigator Group Dr. Ivana Kim Dr. Brian Marr Boston, MA New York, NY Dr. Hakan Demirci Dr. Carol Shields Ann Arbor, MI Philadelphia, PA Dr. Tara McCannel Los Angeles, CA Dr. Antonio Capone Jr. Royal Dr. Abdhish Bhavsar Oak, MI Mi